Page last updated: 2024-12-06

brobactam

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth

Brobactam is a beta-lactam antibiotic that acts as a mechanism-based inhibitor of bacterial beta-lactamases. Its mechanism of action involves the formation of a stable covalent adduct with the active site of bacterial beta-lactamases, thus preventing the hydrolysis of penicillin antibiotics. This enhances the efficacy of penicillin antibiotics by protecting them from enzymatic degradation. Brobactam is typically administered in combination with penicillin antibiotics, such as piperacillin, to treat infections caused by beta-lactamase-producing bacteria. It is studied extensively to develop new drugs and treatment strategies for bacterial infections, particularly those resistant to conventional antibiotics. Research focuses on understanding the molecular interactions between brobactam and bacterial beta-lactamases, optimizing its activity, and exploring its potential in combination therapies. It is also a subject of research regarding its potential as a therapeutic agent against various infectious diseases, including pneumonia, urinary tract infections, and skin infections.'

Cross-References

ID SourceID
PubMed CID65754
CHEMBL ID73622
SCHEMBL ID669135
MeSH IDM0069205

Synonyms (19)

Synonym
brobactam
CHEMBL73622
6-bromopenicillanic acid
(2s,5r,6r)-6-bromo-3,3-dimethyl-7-oxo-4-thia-1-azabicyclo[3.2.0]heptane-2-carboxylic acid
(2s,5r,6r)-6-bromo-3,3-dimethyl-7-oxo-4-thia-1-azabicyclo(3.2.0)heptane-2-carboxylic acid
26631-90-3
brobactamum [latin]
unii-6i6jcf8eoe
brobactam [inn]
brobactamum
einecs 247-856-3
6i6jcf8eoe ,
SCHEMBL669135
DTXSID90181175
AKOS030242189
DAVPSCAAXXVSFU-ALEPSDHESA-N
bdbm50212641
Q27264948
4-thia-1-azabicyclo[3.2.0]heptane-2-carboxylic acid, 6-bromo-3,3-dimethyl-7-oxo-, (2s,5r,6r)-

Research Excerpts

Compound-Compound Interactions

ExcerptReferenceRelevance
"The antibacterial activity of ampicillin against Enterobacteriaceae strongly increased when combined with 6 beta-bromopenicillanic acid (BPA) or clavulanic acid (CA)."( In vitro activity of ampicillin alone and in combination with different concentrations of 6 beta-bromopenicillanic acid, clavulanic acid and mecillinam.
Houben, AW; Stobberingh, EE; van Boven, CP, 1987
)
0.27
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (21)

TimeframeStudies, This Drug (%)All Drugs %
pre-199014 (66.67)18.7374
1990's6 (28.57)18.2507
2000's1 (4.76)29.6817
2010's0 (0.00)24.3611
2020's0 (0.00)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials0 (0.00%)5.53%
Reviews1 (4.76%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other20 (95.24%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]